Table 3.
Metabolic data over time for the Male-to-Female patient population.
| Parameter | Baseline | Visit 1 (3- 6months) |
Visit 2 (6-18 months) |
|---|---|---|---|
| N | 33 | 30 | 15 |
| BMI (kg/m2) | 28.8 ± 1.4 | 29.4 ± 1.5 | 27.7 ± 1.9 |
| sBP (mmHg) | 131 ± 3 | 129 ± 2 | 125 ± 4 |
| dBP (mm Hg) | 82 ± 2 | 80 ± 2 | 77 ± 3 |
| TC (mg/dL) | 171 ± 7 | 176 ± 9 | 194 ± 10 |
| HDL (mg/dL) | 41 ± 2 | 47 ± 2** | 52 ± 5 |
| LDL (mg/dL) | 103 ± 6 | 106 ± 8 | 116 ± 12 |
| TG (mg/dL) | 130 ± 13 | 115 ± 11 | 134 ± 21 |
| K (mmol/L) | 4.09 ± 0.06 | 4.12 ± 0.07 | 4.22 ± 0.08 |
| Creat (mg/dL) | 0.90 ± 0.03 | 0.85 ± 0.03* | 0.83 ± 0.03 |
| Ca (mg/dL) | 9.5 ± 0.1 | 9.5 ± 0.1 | 9.6 ± 0.1 |
| ALT (U/L) | 27 ± 3 | 28 ± 3 | 24 ± 4 |
| AST (U/L) | 23 ± 1 | 22 ± 2 | 23 ± 3 |
|
Estrogen use
by po (N; avg daily dose) |
0 | 18 (56%); 1.44 mg/day |
7 (50%); 1.71 mg/day |
|
Estrogen use
by patch (N; avg daily dose |
0 | 7 (22%); 0.1 mg/day |
2 (14%); 0.1 mg/day |
|
Estrogen use
by injection (N; avg daily dose) |
0 | 7 (22%); 1.21 mg/day |
5 (36%); 1.18 mg/day |
|
Spironolactone
use (N; avg daily dose) |
0 | 23; 104 mg/day | 14; 114 mg/day |
*
signifies p < 0.05, using a paired t-test compared to baseline visit.
**
signifies p < 0.01 using a paired t-test compared to baseline visit.
N = sample size; BMI = body mass index; sBP = systolic blood pressure; dBP = diastolic blood pressure; TC = total cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglycerides; K = potassium; Creat = creatinine; Ca = calcium; ALT = alanine transaminase; and AST = aspartate transaminase. Data shown is average ± SEM